Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 31, Number 9—September 2025
Dispatch
CYP2D6 Genotype and Primaquine Treatment in Patients with Malaria, Venezuela
Table
Genotypes CYP2D6*4 and CYP2D6*6 and predicted phenotypes during primaquine treatment in patients with suspected malaria, Venezuela
Genotype | Activity score | Predicted phenotype | Nonmalaria patients, no. (%), n = 52 | Malaria patients, no. (%), n = 44 |
---|---|---|---|---|
1*1 | 2 | Normal metabolizer | 39 (75) | 33 (75) |
1*4 | 1 | Intermediate metabolizer | 9 (17.31) | 8 (18.19) |
1*6 | 1 | Intermediate metabolizer | 2 (3.85) | 1 (2.27) |
4*4 | 0 | Poor metabolizer | 1 (1.92) | 1 (2.27) |
6*6 | 0 | Poor metabolizer | 0 | 1 (2.27) |
6*4 | 0 | Poor metabolizer | 1 (1.92) | 0 |
1These authors were co–principal investigators.
Page created: July 03, 2025
Page updated: August 04, 2025
Page reviewed: August 04, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.